ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 57 for:    Friedreich's Ataxia

Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02316314
Recruitment Status : Recruiting
First Posted : December 12, 2014
Last Update Posted : May 25, 2017
Sponsor:
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:
Friedreich's ataxia (FRDA) is an autosomal recessive disease characterized by loss of coordination and cardiomyopathy. It is the most common form of inherited ataxia with an incidence in 1/50,000 in the Caucasian population. FRDA is associated with progressive damage to the nervous system, resulting in symptoms ranging from gait disturbance to speech problems, as well as diabetes and heart disease. The heart disease manifests as cardiomyopathy, and is responsible for approximately 60% of deaths from FRDA. This study is designed to characterize the cardiac manifestations of the disease using exercise, MRI, ECHO and serum parameters, in the context of the neurological disease.

Condition or disease Intervention/treatment
Friedreich's Ataxia Procedure: Cardiac magnetic resonance imaging (CMR) Procedure: Exercise-stress test Procedure: Echocardiogram (ECHO) Procedure: Cardiac-related blood studies

Detailed Description:
The focus of this study is to assess cardiac dysfunction in individuals with FRDA using 4 modalities: hand crank exercise, cardiac magnetic resonance (CMR) imaging, echocardiography (ECHO), and serum measurements of cardiac status, including high sensitivity troponin, a measure of cardiac myocyte damage; N-terminal prohormone of brain natriuretic peptide (NT-proBNP), a measure of heart failure; and creatine phosphokinase (CPK), a general measure of muscle damage. While there have been individual studies of some of these modalities, there are no studies that correlate these parameters and it is not known which parameters are more sensitive to cardiac dysfunction. This preliminary study will help define the parameters that will be most useful in assessing the cardiac involvement in FRDA.

Study Type : Observational
Estimated Enrollment : 45 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)
Study Start Date : December 2014
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017


Group/Cohort Intervention/treatment
Individuals diagnosed with FRDA
Individuals diagnosed with FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies
Procedure: Cardiac magnetic resonance imaging (CMR)
CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called "contrast" to get a better picture of the heart.
Procedure: Exercise-stress test
You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.
Procedure: Echocardiogram (ECHO)
An echocardiogram is an ultrasound of the heart done at rest.
Procedure: Cardiac-related blood studies
The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).
Healthy controls
Individuals without FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies
Procedure: Cardiac magnetic resonance imaging (CMR)
CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called "contrast" to get a better picture of the heart.
Procedure: Exercise-stress test
You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.
Procedure: Echocardiogram (ECHO)
An echocardiogram is an ultrasound of the heart done at rest.
Procedure: Cardiac-related blood studies
The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).



Primary Outcome Measures :
  1. Level of troponin, BNP, and CPK in blood [ Time Frame: 30 minutes ]
    Average the levels of troponin for each subject

  2. echocardiogram [ Time Frame: 2 hour ]
    Evaluate the results of subject's Echo cardiograms

  3. exercise-stress test [ Time Frame: 2 hour ]
    Evaluate off the results of the exercise-stress test


Biospecimen Retention:   Samples With DNA

Blood Amount: Up to 88 mL of blood will be collected for the entire study and up to 57 mL of blood will be collected for a single visit. (CBC = 5 mL per visit; Clotting = 6 mL per visit; Chemistry = 7 mL per visit; Liver function = 5 mL per visit; Cardiac enzymes = 5 mL per visit; Future serum = 3 mL per visit; Genetic analysis = 4 mL; HbA1c = 5mL; HIV test = 7 mL; and Anti-AAVrh.10 = 10 mL)

Urine Amount: Approximately 24 mL of urine will be collected for the entire study and approximately 12 mL of urine will be collected for a single visit.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The study will be composed of individuals with FRDA and individuals without. Individuals without FRDA will be age, gender and ethnicity matched to the individuals with FRDA.
Criteria

Friedreich's Ataxia

Inclusion Criteria:

  • Males and females, age 18 to 30
  • Willing and able to provide informed consent
  • Definitive diagnosis of FRDA, based on clinical phenotype and genotype
  • Ability to complete study parameters

Exclusion Criteria:

  • Signs and symptoms of cardiac failure
  • Moderate to severe atrial or ventricular arrythmias
  • History of angina pectoris
  • Inability to undergo MRI
  • History of uncontrolled diabetes
  • History of abnormal kidney function
  • Enrollment in a cardiac clinical trial
  • Unable to sit with back support
  • Pregnant or nursing females

Normal controls

Inclusion Criteria:

- Ability to complete study parameters

Exclusion Criteria:

  • Not deemed in good overall health
  • Pregnant or nursing females

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02316314


Contacts
Contact: Grace Mammen, BA, CCRP 646-962-2676 gwm2004@med.cornell.edu
Contact: Michelle Yuan, BA 646-962-2672 miy2006@med.cornell.edu

Locations
United States, New York
Weill Cornell Medical College Recruiting
New York, New York, United States, 10021
Contact: Michelle Yuan, BA    646-962-2672    miy2006@med.cornell.edu   
Contact: Grace Mammen, BA, CCRP    646-962-2672    gwm2004@med.cornell.edu   
Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Principal Investigator: Ronald Crystal, MD Weill Medical College of Cornell University

Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT02316314     History of Changes
Other Study ID Numbers: 1408015429
First Posted: December 12, 2014    Key Record Dates
Last Update Posted: May 25, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Weill Medical College of Cornell University:
Friedreich's Ataxia
Cardiomyopathy

Additional relevant MeSH terms:
Ataxia
Cerebellar Ataxia
Friedreich Ataxia
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Cerebellar Diseases
Brain Diseases
Central Nervous System Diseases
Spinocerebellar Degenerations
Spinal Cord Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Mitochondrial Diseases
Metabolic Diseases